Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease

Clin Gastroenterol Hepatol. 2023 Mar;21(3):838-840.e2. doi: 10.1016/j.cgh.2021.12.020. Epub 2021 Dec 20.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Crohn Disease* / drug therapy
  • Endoscopy
  • Humans
  • Remission Induction
  • Treatment Outcome
  • Ustekinumab* / therapeutic use

Substances

  • Ustekinumab
  • Antibodies, Monoclonal, Humanized